PHILLIPSBURG, N.J., May 21 /PRNewswire/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) announced today it has received Federal Trade Commission approval under the Hart-Scott Rodino (HSR) Act, clearing AVANT's proposal to award Pfizer (NYSE: PFE) exclusive rights to CDX-110, an investigational vaccine currently under development.
On April 16, 2008, Pfizer, Inc. and Celldex announced that they entered into an agreement under which Pfizer would be granted an exclusive worldwide license to CDX-110, currently being evaluated in a Phase 2 study for the treatment of glioblastoma multiforme (GBM). The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications.
CDX-110 is designed to induce or enhance the body's immune responses against EGFRvIII resulting in destruction of tumor cells that express the variant receptor. Single arm Phase 2 clinical trials of CDX-110 in combination with the current standard treatment for patients with GBM have been conducted. Updated clinical data will be released at the American Society for Clinical Oncology Meeting in Chicago on June 2, 2008. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics and Celldex Therapeutics combined during the
first quarter of 2008. AVANT is a Nasdaq-listed company discovering and
developing innovative vaccines and targeted immunotherapeutics for the
treatment of cancer, infectious and inflammatory diseases. AVANT focuses on
the use of tumor-specific targets and human monoclonal antibodies (mAbs) to
precisely deliver therapeutic agents through its novel "targeted
immunization" approach. In addition, AVANT is exploiting its access to
proprietary human antibody technology for development of therapeutic
monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of
products in varying stages of development. Identification of the potential
of EGFRvIII in cancer diagnosis, prevention and therapy was based on the
collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns
Hopkins University and Dr. Darell Bigner at Duke University. Application of
this discovery toward the development of the CDX-110 vaccine was further
advanced by Dr. John Sampson and his colleagues at the Duke University
Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD
Anderson Cancer Center. AVANT has several other product candidates in its
development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting
Technology(TM), which is in two Phase 1 clinical trials for patients
with advanced pancreatic, bladder, breast and colon cancer;
-- TP10, a complement inhibitor, in development for transplantation and
other indications; and
-- Three candidates based on oral, rapidly-protecting, single-dose and
temperature-stable vaccine technology, including combination vaccines
for travellers, the military and global health needs.
AVANT has three commercialized products, including Rotarix(R)
(partnered with GSK) for the prevention of rotavirus infection and two
human food safety vaccines for reducing salmonella infection in chickens
and eggs. Additional information on AVANT Immunotherapeutics, Inc. can be
obtained through its web site http://www.avantimmune.com.
AVANT Immunotherapeutics, Inc.
Anthony S. Marucci, 781-433-0771
Interim President and CEO
(212) 477-9007 x21
|SOURCE Celldex Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved